Clinical Guidance for Disease-Modifying Immunotherapy in Children and Adolescents With New-Onset (Stage 3) Type 1 Diabetes
Diabetes Care · 11.11.2026
DOI: 10.2337/dci26-0061 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 11.11.2026. Verfasst von Kimber M Simmons und 13 weiteren Autor:innen. Beteiligte Einrichtung: Barbara Davis Center for Diabetes, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO.
Themen: Diabetes mellitus, Kinderkrankenpflege
Abstract (Originalsprache)
The 2026 U.S. approval of teplizumab, for children and adolescents aged 8–17 years with recently diagnosed stage 3 type 1 diabetes, changes the first weeks after diagnosis. Clinicians must treat hyperglycemia and teach lifelong care skills while considering whether to preserve residual β-cell function. Teplizumab is the current clinical exemplar, although the implementation challenges extend beyond one agent. This article addresses who should lead care, how to approach eligibility and timing, how to assess β-cell reserve and infection risk, how to sequence treatment with diabetic ketoacidosis recovery and early education, and how to monitor treatment safely. Teplizumab-specific recommendations are identified, with broader principles framed for adaptation across health systems.
Autor:innen und Institutionen
- Barbara Davis Center for Diabetes, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO.
- University of Colorado Anschutz Medical Campus, Aurora, CO.
- NYU Langone Health, New York, NY.
- Division of Pediatric Endocrinology, University of California San Diego and Rady Children's Hospital-San Diego, San Diego, CA.
- Department of Pediatrics, University of California, San Francisco, San Francisco, CA.
- Department of Immunobiology, Yale School of Medicine, New Haven, CT.
ORCID-Profile: Kimber M Simmons, Carla Demeterco-Berggren, Stephen Gitelman, Kevan C Herold, Shideh Majidi, Jennifer L Sherr, Emily K Sims, Michael J Haller
Zitieren
APA
Simmons, K. M., Weinberg, A., Breidbart, E., Demeterco-Berggren, C., Gitelman, S., Herold, K. C., Majidi, S., Moore, D., Ogbonnaya-Whittlesey, A., Patel, N., Sherr, J. L., Sims, E. K., Wintergerst, K., & Haller, M. J. (2026). Clinical Guidance for Disease-Modifying Immunotherapy in Children and Adolescents With New-Onset (Stage 3) Type 1 Diabetes. Diabetes Care. https://doi.org/10.2337/dci26-0061
Vancouver
Simmons KM, Weinberg A, Breidbart E, Demeterco-Berggren C, Gitelman S, Herold KC, et al. Clinical Guidance for Disease-Modifying Immunotherapy in Children and Adolescents With New-Onset (Stage 3) Type 1 Diabetes. Diabetes Care. 2026. doi:10.2337/dci26-0061
BibTeX
@article{Simmons2026,
author = {Simmons, Kimber M and Weinberg, Adriana and Breidbart, Emily and Demeterco-Berggren, Carla and Gitelman, Stephen and Herold, Kevan C and Majidi, Shideh and Moore, Daniel and Ogbonnaya-Whittlesey, Amara and Patel, Neha and Sherr, Jennifer L and Sims, Emily K and Wintergerst, Kupper and Haller, Michael J},
title = {Clinical Guidance for Disease-Modifying Immunotherapy in Children and Adolescents With New-Onset (Stage 3) Type 1 Diabetes},
journal = {Diabetes Care},
year = {2026},
doi = {10.2337/dci26-0061}
}
EUVIMED